Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients
Novartis announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in COPD patients. February 22, 2018